Biguanides market to reach $5.97 billion by 2030

18 hours ago
Biguanides market to reach $5.97 billion by 2030
By AI, Created 16:00 UTC, Nov 20, 2026, AGP -

The global biguanides market is projected to grow from $5.11 billion in 2025 to $5.28 billion in 2026, as demand rises for diabetes and metabolic disorder treatments. Asia-Pacific led the market in 2025, while the Middle East and Africa are expected to grow the fastest through 2030.

Why it matters: - Biguanides remain a core drug class for managing type 2 diabetes, a disease that continues to expand worldwide. - The market’s growth also reflects broader demand for metabolic disorder treatments, including use in polycystic ovary syndrome. - Rising diabetes care needs are pushing more interest in oral antidiabetic drugs, generic options and remote management tools.

What happened: - The Business Research Company said the biguanides market is set to rise from $5.11 billion in 2025 to $5.28 billion in 2026. - The report projects the market will reach $5.97 billion by 2030. - The forecast implies a 3.4% CAGR from 2025 to 2026 and a 3.1% CAGR through 2030. - Asia-Pacific was the largest regional market in 2025. - The Middle East and Africa are expected to be the fastest-growing regions during the forecast period. - The report covers South East Asia, Western Europe, Eastern Europe, North America and South America as part of the global market view.

The details: - Biguanides reduce hepatic glucose production and improve insulin sensitivity. - The drugs are mainly prescribed for type 2 diabetes. - The class is also used for other metabolic disorders, including PCOS. - Historical growth has been driven by higher type 2 diabetes prevalence, greater public awareness of metabolic conditions, wider access to generic biguanides, increased use of oral antidiabetic drugs and advances in liver-targeted therapies. - Future growth drivers include personalized medicine, telemedicine for diabetes care, more PCOS cases, combination drug therapies and government chronic disease initiatives. - The report highlights several trend areas, including personalized diabetes management, broader uses beyond type 2 diabetes, home healthcare, remote patient monitoring and lower-cost generic biguanides. - The UK Office for Health Improvement & Disparities reported in March 2024 that the share of people completing all eight recommended care processes rose 22% for type 1 diabetes and 21% for type 2 diabetes between March 2022 and March 2023. - The same update showed the share of patients reaching target HbA1c levels hit a record 37.9%. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The forecast suggests the market is still growing, but not at a breakneck pace, which points to a mature therapeutic category with steady demand rather than a breakout one. - The emphasis on telemedicine, remote monitoring and home care shows how diabetes treatment is shifting beyond prescriptions alone toward ongoing disease management. - The inclusion of broader indications and personalized medicine suggests suppliers are looking for growth beyond the traditional metformin-led diabetes market.

What's next: - Demand will likely track diabetes prevalence, treatment access and adoption of digital care tools. - The report’s forecast window through 2030 suggests continued but moderate expansion rather than rapid disruption. - More competition may come from generic pricing, combination therapies and products aimed at wider metabolic uses. - More information - The full report

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Asia News Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Asia News Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.